Clinical Trials Logo

Filter by:
NCT ID: NCT05472805 Completed - Clinical trials for Chronic Kidney Diseases

Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio to Predict Carotid Intima-Media Thickness in Chronic Kidney Disease Patients

Start date: January 1, 2022
Phase:
Study type: Observational

This study aims to determine whether the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can be used as predictors of coronary heart disease (CHD) in CKD patients undergoing dialysis at Moewardi General Hospital Surakarta. It was hypothesized that NLR and PLR, which have been identified as inflammatory biomarkers, would be significantly related to increased arotid intima-media thickness (CIMT) in CKD patients undergoing dialysis. This study is an observational analytic study using a cross-sectional approach conducted at department of renal-hypertension and hemodialysis unit in Moewardi General Hospital in Surakarta, Indonesia from January to July 2022.

NCT ID: NCT05468879 Completed - Drug Use Clinical Trials

Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

Start date: September 21, 2020
Phase: N/A
Study type: Interventional

The study was conducted toinvestigate whether the bioavailability of 3 mg Glimepiride Tablet Manufactured by PT. Harsen Laboratories was bioequivalent to the reference product, 3 mg Amaryl® Tablet Manufactured by PT. Aventis Indonesia Pharma, Indonesia.

NCT ID: NCT05467969 Completed - Clinical trials for Educational Problems

Teleteaching on Clinical Procedural Skills

Start date: September 1, 2020
Phase:
Study type: Observational

This study aims to develop a model of teleteaching and teleassessment for clinical procedural skills, consisted of teleteaching design making and teleteaching intervention was conducted in September 2020 - February 2021 at a tertiary center Dr. Cipto Mangunkusumo Hospital/ Faculty of Medicine Universitas Indonesia.

NCT ID: NCT05465499 Completed - ERAS Clinical Trials

Preliminary Survey in Preparation for the Implementation of ERAS at Dr Soetomo Hospital

Start date: March 23, 2022
Phase:
Study type: Observational

This study aims to analyze the readiness of the team that will support the ERAS application at Regional General Academic Hospital Dr Soetomo.

NCT ID: NCT05455164 Completed - Dietary Exposure Clinical Trials

The Effect of Eucaloric High-Protein Fiber Diet in Healthy Adults: A Repeated Single-Arm Clinical Trial

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The aims of this study is to investigate the effect of eucaloric high protein and fiber diet on healthy subjects.

NCT ID: NCT05449080 Completed - Genotype Clinical Trials

Disorders of Sex Development (DSD) 46.XY in Three Siblings

Start date: October 1, 2021
Phase:
Study type: Observational

This is a case series of three siblings with DSD 46,XY with relevant discussion

NCT ID: NCT05448924 Completed - Clinical trials for Growth Hormone Deficiency

Isolated Growth Hormone Deficiency and Amennorrhea

Start date: December 1, 2021
Phase:
Study type: Observational

This is a case report of a 14-year old female with no menstruation history.

NCT ID: NCT05444790 Completed - Malaria Clinical Trials

Abbott NxTekTM Malaria RDT WHO Prequalification Study

Start date: June 30, 2022
Phase:
Study type: Observational

Since their introduction in the late 90's, rapid diagnostic tests (RDTs) have dramatically improved our ability to control malaria but proved insufficient to support elimination efforts because of their limited sensitivity, especially for P. vivax. In addition, the spread of P. falciparum parasites lacking hrp2 gene jeopardizes the long-term use of P. falciparum-specific HRP2-based RDTs. A partnership between Abbott, FIND, PATH, and the Bill and Melinda Gates Foundation (BMGF) is addressing these limitations by developing two novel malaria RDTs with improved pLDH detection: a P. falciparum-specific test targeting both the HRP2 and PfLDH antigens on a single test line (NxTekTM Malaria P.f plus Rapid Diagnostic Test Device), and a P. falciparum/P. vivax combo test additionally targeting the PvLDH antigen on a second test line (NxTekTM Malaria P.f/P.v. plus Rapid Diagnostic Test Device). These new combo tests with improved pLDH detection may provide added value compared to currently available malaria RDTs, especially in settings where current tests prove to be insufficient due to hrp2 deletion or high burden of P. vivax malaria. Abbott, PATH, and FIND will conduct a prospective evaluation of NxTekTM Malaria P.f plus and NxTekTM Malaria P.f/P.v plus RDTs in malaria-endemic countries to assess their clinical performance for detection of malaria and usability in their intended-use settings. This is in support of a submission for WHO Prequalification.The purpose of this synopsis is to describe key points of alignment in study design and conduct across the portfolio of studies.

NCT ID: NCT05433285 Completed - COVID-19 Clinical Trials

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Start date: June 7, 2022
Phase: Phase 3
Study type: Interventional

Observer-blind, randomized, active-controlled prospective intervention study

NCT ID: NCT05430087 Completed - Clinical trials for Systemic Lupus Erythematosus

Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with a relatively high mortality and morbidity rate, especially in developing countries such as Indonesia. In Indonesia, a previous study demonstrated that almost 71% of SLE patients experience hypovitaminosis D, with serum vitamin D 25 levels less than 30 ng/ml. Several factors contribute to the low vitamin D levels among SLE patients. Less exposure to sunlight or insufficient vitamin D intake contributes to SLE patients low vitamin D levels. Some other studies also revealed that vitamin D metabolism gene polymorphisms are also associated with patients with SLE. Vitamin D is essential for bone health and has an essential role in immune system modulation and controlling autoimmune diseases, including SLE. Another study demonstrates that curcumin supplementation in premenopausal women and dysmenorrhea improves vitamin D levels. Despite the promising properties of curcumin in improving vitamin D biological actions, our previous study reveals that the addition of curcumin in vitamin D administration do not significantly improve the disease activity or cytokine imbalance in SLE patients. The synergistic property of curcumin with vitamin D in regulating immune cells is an open opportunity for researchers to increase the response to vitamin D3 therapy. Several studies have reported the efficacy of vitamin D or curcumin for SLE treatment. However, none mentioned the combination of curcumin added with piperine and vitamin D3. We hypothesized that adding curcumin piperine with vitamin D3 as a complementary treatment in SLE patients would improve the clinical symptoms or cytokine balance among SLE patients. Therefore, this study aims to observe the effects of adding curcumin-piperine with vitamin D3 in clinical outcomes and cytokines levels in SLE patients with hypovitaminosis D.